Enlivex Therapeutics shares rise 12.36% premarket after announcing 3-month topline data from Phase IIa trial.

Enlivex Therapeutics Ltd. rose 12.36% in premarket trading, with the company announcing that it will host a webinar to present and discuss 3-month topline results from the Phase IIa stage of its ENX-CL-05-001 trial. The webinar will feature a detailed analysis of the data from the multi-center, randomized, double-blind, placebo-controlled study evaluating Allocetra™ in patients with moderate to severe knee osteoarthritis.